ONCOLOGY

The new tyrosine kinase inhibitor significantly improved PFS, response rate vs placebo.

It is the first adjuvant therapy to show a benefit over placebo in this population.

Two-thirds of colorectal cancer patients surveyed said they did not receive any nutritional advice or support from their health care team.

A prospective observational cohort study of 1,171 patients with previously untreated locally advanced or metastatic colorectal cancer.

A systematic review and meta-analysis of randomised controlled trials.

The optimal multimodality treatment sequencing for locally advanced rectal cancer remains debated.

This is the first large study of adjuvant chemotherapy after neoadjuvant FOLFIRINOX.

Phase 3 data are insufficient to guide later lines of treatment.

Chemotherapy is associated with less than a year survival and significant toxicity.

A spin-out company has been established to fast-track the drug into clinical testing within two years.

Patients may need counseling about medical and nutritional interventions.

Efficacy of NAC with standard surgery was already established.

Staging the patient’s physiological state using derivative SIR biomarkers is important.

The draft guidance is open for public comment until 25 September 2020